BR9815171A - Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. - Google Patents
Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios.Info
- Publication number
- BR9815171A BR9815171A BR9815171-1A BR9815171A BR9815171A BR 9815171 A BR9815171 A BR 9815171A BR 9815171 A BR9815171 A BR 9815171A BR 9815171 A BR9815171 A BR 9815171A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkylalkyl
- cycloalkenyl
- cycloalkyl
- Prior art date
Links
- 208000006673 asthma Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 4
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 2
- 125000005055 alkyl alkoxy group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 where said al quil Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Patente de Invenção de "de <B>"COMPOSTO INIBIDOR DE PDE IV APLICáVEL NO TRATAMENTO DE DOENçAS, PARTICULAMENTE DE ASMA, EM MAMìFEROS E MéTODO PARA TRATAR UM PACIENTE SOFRENDO ESTADOS DOENTIOS"<D>. A invenção apresenta a seguinte fórmula: onde R³ é selecionado do grupo consistindo de C~ 1-10~ alquil, C~ 1-10~ alquenil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; ou benzil, onde o referido benzil é opcionalmente substituído em uma ou duas posições por halogênio, alcoxi, cicloalcoxi, ou policicloalquil e onde a referida metade do alquil do referido alcoxi ou cicloalcoxi é opcionalmente substituída em uma posição por hidroxi; O R^ 8^ é selecionado do grupo consistindo de C~ 1-10~ alquil, C~ 1-10~ alquenil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; ou benzil, onde o referido benzil é opcionalmente substituído em uma ou duas posições por halogênio, alcoxi, cicloalcoxi, ou policicloalquil e onde a referida metade do alquil do referido alcoxi ou cicloalcoxi é opcionalmente substituída em uma posição por hidroxi; O R^ 6a^ e R^ 6b^ são independentemente selecionados do grupo consistindo de hidrogênio, C~ 1-10~ alquil, C~ 3-10~ cicloalquil, C~ 4-10~ cicloalquilalquil ou C~ 3-10~ cicloalquenil, onde o referido alquil, alquenil, cicloalquil, cicloalquilalquil ou cicloalquenil é opcionalmente substituído em uma posição por hidroxi; desde que pelo menos um dos referidos substituintes do R³, R^ 8^, R^ 6a^ e R^ 6b^ seja ainda substituído pelo referido hidroxil;
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6937197P | 1997-12-12 | 1997-12-12 | |
| PCT/US1998/026293 WO1999031102A1 (en) | 1997-12-12 | 1998-12-11 | Purine derivatives having phosphodiesterase iv inhibition activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9815171A true BR9815171A (pt) | 2000-10-10 |
Family
ID=22088545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
| BR9815171-1A BR9815171A (pt) | 1997-12-12 | 1998-12-11 | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9815170-3A BR9815170A (pt) | 1997-12-12 | 1998-12-10 | "método de obter composto aplicável no tratamento de asma em mamìferos" |
| BR9815169-0A BR9815169A (pt) | 1997-12-12 | 1998-12-11 | "método para formar um composto e composto aplicável no tratamento de asma em mamìferos, composição farmacêutica, método para efetivar a inibição seletiva de pde iv em mamìferos de estado de doença e método de tratar mamìfero sofrendo de estado de doença." |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6057445A (pt) |
| EP (3) | EP1044201A4 (pt) |
| JP (5) | JP2002508378A (pt) |
| KR (3) | KR100349385B1 (pt) |
| CN (3) | CN1294590A (pt) |
| AT (1) | ATE244243T1 (pt) |
| AU (5) | AU1723099A (pt) |
| BR (3) | BR9815170A (pt) |
| CA (3) | CA2313004A1 (pt) |
| DE (3) | DE19882893T1 (pt) |
| DK (1) | DK1045849T3 (pt) |
| ES (1) | ES2202924T3 (pt) |
| GB (2) | GB2346879B (pt) |
| HU (3) | HUP0301166A2 (pt) |
| NO (1) | NO20002998L (pt) |
| PL (1) | PL341108A1 (pt) |
| PT (1) | PT1045849E (pt) |
| TR (1) | TR200001706T2 (pt) |
| WO (5) | WO1999031103A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413975B1 (en) * | 1999-04-02 | 2002-07-02 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase iv inhibition activity |
| ATE279113T1 (de) * | 1999-08-12 | 2004-10-15 | Euro Celtique Sa | Hypoxanthin- und thiohypxanthin-verbindungen |
| CN100439370C (zh) * | 2001-02-08 | 2008-12-03 | 记忆药物公司 | 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤 |
| FR2842809A1 (fr) * | 2002-07-26 | 2004-01-30 | Greenpharma Sas | NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION |
| WO2004014911A1 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
| WO2004014913A2 (en) * | 2002-08-08 | 2004-02-19 | Memory Pharmaceuticals Corporation | Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| US20040063938A1 (en) * | 2002-09-30 | 2004-04-01 | Pfizer Inc | Process for preparing haloalkyl pyrimidines |
| JP2007523868A (ja) * | 2003-07-10 | 2007-08-23 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製の阻害薬として有用な置換アリールチオウレア誘導体類 |
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| WO2005058898A2 (en) * | 2003-12-16 | 2005-06-30 | Ranbaxy Laboratories Limited | Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| DE102006033572A1 (de) | 2006-07-20 | 2008-01-24 | Bayer Cropscience Ag | N'-Cyano-N-halogenalkyl-imidamid Derivate |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| CA2709550A1 (en) | 2007-12-17 | 2009-06-25 | Lux Innovate Limited | Compositions and methods for maintenance of fluid conducting and containment systems |
| PE20120003A1 (es) * | 2009-01-30 | 2012-02-12 | Glaxosmithkline Llc | Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| HUE035069T2 (en) * | 2011-12-28 | 2018-05-02 | Global Blood Therapeutics Inc | Substituted benzaldehyde compounds and their use to increase tissue oxygenation |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| KR20150132146A (ko) | 2013-03-15 | 2015-11-25 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2903022C (en) | 2013-03-15 | 2021-11-09 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 |
| TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案 |
| WO2017123766A1 (en) * | 2016-01-12 | 2017-07-20 | Sperovie Biosciences, Inc. | Compounds and compositions for the treatment of disease |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3860975B1 (en) | 2018-10-01 | 2023-10-18 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| RU2746012C2 (ru) * | 2019-05-13 | 2021-04-05 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Антидепрессантное средство для коррекции нежелательных побочных эффектов нейролептиков |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2903455A (en) | 1959-09-08 | Jdnviiiiaisnvhi jo | ||
| US2956998A (en) | 1960-10-18 | Adenine derivatives and process | ||
| US3215696A (en) | 1965-11-02 | Substituted adenines -and preparation thereof | ||
| US2844577A (en) | 1958-07-22 | Certificate of correction | ||
| US2697709A (en) | 1951-06-14 | 1954-12-21 | Burroughs Wellcome Co | Mercapto heterocycles and method of making |
| US2691654A (en) | 1952-06-11 | 1954-10-12 | Buroughs Wellcome & Co U S A I | Amino heterocycles and method of making |
| US2966488A (en) * | 1956-07-30 | 1960-12-27 | Shive William | Substituted alkylaminopurines |
| US2957875A (en) | 1957-11-18 | 1960-10-25 | Upjohn Co | Derivatives of purine |
| US3079378A (en) | 1960-02-01 | 1963-02-26 | Upjohn Co | Acylated psicofuranosyladenines |
| NL262940A (pt) | 1960-03-31 | |||
| US3135753A (en) | 1961-05-10 | 1964-06-02 | Burroughs Wellcome Co | Alkylthiopurines and method |
| FR1548252A (pt) | 1961-10-13 | 1968-12-06 | ||
| IL24679A (en) | 1965-11-24 | 1971-10-20 | Yissum Res Dev Co | Derivatives of 3-methyl purine and methods of preparing the same |
| US3669979A (en) | 1967-12-14 | 1972-06-13 | Gaf Corp | Novel process for the production of 2-benzothiazolyl-phenol and derivatives thereof employing phosphorus trichloride as a catalyst |
| US3952001A (en) | 1970-07-01 | 1976-04-20 | The Boots Company Limited | 1-Carbamoyl-1,2,4-triazoles |
| JPS5121529A (ja) | 1974-08-16 | 1976-02-20 | Hitachi Ltd | Pirorinsandometsukizeiseihimakuboshiho |
| USRE31429E (en) | 1977-02-14 | 1983-10-25 | Merck & Co., Inc. | Process for preparation of 9-(dihalobenzyl)adenines |
| GB2041359B (en) * | 1979-01-10 | 1982-12-15 | Ici Ltd | Purine derivatives and their use in the defoliation of cotton plants |
| US4241063A (en) | 1979-08-06 | 1980-12-23 | Bristol-Myers Company | Purine derivatives and their use as bronchodilators |
| US4361699A (en) | 1981-09-28 | 1982-11-30 | Merck & Co., Inc. | Novel process for the preparation of N6 -alkyl-arprinocid |
| US4407802A (en) | 1981-09-28 | 1983-10-04 | Merck & Co., Inc. | 6-Amidino-9-substituted benzyl purines |
| GB2120065B (en) | 1982-04-27 | 1986-01-02 | Michael Frederick Huber | Heating plants |
| US4492592A (en) | 1983-06-06 | 1985-01-08 | Shell Oil Company | Combined desiccation of substantially supercritical CO2 |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | プリン誘導体 |
| US4883801A (en) | 1984-09-07 | 1989-11-28 | The General Hospital Corporation | Xanthine derivative pest control agents |
| GB8510758D0 (en) | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| HU215433B (hu) | 1986-04-29 | 2000-05-28 | Pfizer Inc. | Eljárás új 2-oxo-5-fenil-pirimidin-származékok előállítására |
| GB8618931D0 (en) | 1986-08-02 | 1986-09-10 | Euro Celtique Sa | 6-thioxanthines |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
| EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
| US4971972A (en) | 1989-03-23 | 1990-11-20 | Schering Corporation | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| ATE195739T1 (de) | 1989-10-20 | 2000-09-15 | Kyowa Hakko Kogyo Kk | Kondensierte purinderivate |
| US5117830A (en) | 1990-11-08 | 1992-06-02 | Whitby Research, Inc. | Method of determining viability of tissue |
| US5177074A (en) | 1991-03-26 | 1993-01-05 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| DE69322254T2 (de) | 1992-01-13 | 1999-04-29 | Smithkline Beecham Corp., Philadelphia, Pa. 19101 | Pyridyl-substituierte imidazole |
| IL104369A0 (en) | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
| WO1993025517A1 (en) | 1992-06-15 | 1993-12-23 | Celltech Limited | Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors |
| JP3775684B2 (ja) | 1992-07-28 | 2006-05-17 | ローン−プーラン・ロレ・リミテツド | 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物 |
| GB9222253D0 (en) | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
| JP3100984B2 (ja) | 1992-12-02 | 2000-10-23 | ファイザー・インク． | 選択的ｐｄｅ▲下ｉ▼▲下ｖ▼阻害物質としてのカテコールジエーテル類 |
| TW263495B (pt) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
| GB9226830D0 (en) | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
| GB9304920D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| DE4309969A1 (de) | 1993-03-26 | 1994-09-29 | Bayer Ag | Substituierte heteroanellierte Imidazole |
| GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
| FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
-
1998
- 1998-12-10 US US09/209,664 patent/US6057445A/en not_active Expired - Fee Related
- 1998-12-10 DE DE19882893T patent/DE19882893T1/de not_active Withdrawn
- 1998-12-10 AU AU17230/99A patent/AU1723099A/en not_active Abandoned
- 1998-12-10 AU AU17228/99A patent/AU1722899A/en not_active Abandoned
- 1998-12-10 CN CN98812098A patent/CN1294590A/zh active Pending
- 1998-12-10 CA CA002313004A patent/CA2313004A1/en not_active Abandoned
- 1998-12-10 JP JP2000539027A patent/JP2002508378A/ja active Pending
- 1998-12-10 AU AU17229/99A patent/AU1722999A/en not_active Abandoned
- 1998-12-10 BR BR9815170-3A patent/BR9815170A/pt not_active Application Discontinuation
- 1998-12-10 WO PCT/US1998/026338 patent/WO1999031103A1/en active Application Filing
- 1998-12-10 JP JP2000539028A patent/JP2002508379A/ja active Pending
- 1998-12-10 HU HU0301166A patent/HUP0301166A2/hu unknown
- 1998-12-10 WO PCT/US1998/026339 patent/WO1999031104A1/en active Application Filing
- 1998-12-10 KR KR1020007005963A patent/KR100349385B1/ko not_active IP Right Cessation
- 1998-12-10 JP JP2000539026A patent/JP2002508377A/ja active Pending
- 1998-12-10 DE DE19882892T patent/DE19882892T1/de not_active Withdrawn
- 1998-12-10 US US09/209,922 patent/US6040447A/en not_active Expired - Lifetime
- 1998-12-10 WO PCT/US1998/026340 patent/WO1999031105A1/en not_active Application Discontinuation
- 1998-12-10 GB GB0013781A patent/GB2346879B/en not_active Expired - Fee Related
- 1998-12-10 GB GB0013780A patent/GB2346878B/en not_active Expired - Fee Related
- 1998-12-10 US US09/209,658 patent/US6037470A/en not_active Expired - Lifetime
- 1998-12-10 EP EP98962064A patent/EP1044201A4/en not_active Withdrawn
- 1998-12-11 CA CA002313150A patent/CA2313150A1/en not_active Abandoned
- 1998-12-11 DE DE69816127T patent/DE69816127T2/de not_active Expired - Fee Related
- 1998-12-11 HU HU0100305A patent/HUP0100305A2/hu unknown
- 1998-12-11 CA CA002314335A patent/CA2314335A1/en not_active Abandoned
- 1998-12-11 BR BR9815169-0A patent/BR9815169A/pt not_active Application Discontinuation
- 1998-12-11 KR KR1020007006328A patent/KR20010032979A/ko not_active Application Discontinuation
- 1998-12-11 CN CN98812064A patent/CN1281458A/zh active Pending
- 1998-12-11 KR KR1020007006407A patent/KR20010033049A/ko not_active Application Discontinuation
- 1998-12-11 AU AU18208/99A patent/AU1820899A/en not_active Abandoned
- 1998-12-11 HU HU0100417A patent/HUP0100417A3/hu unknown
- 1998-12-11 AU AU18159/99A patent/AU747366B2/en not_active Ceased
- 1998-12-11 ES ES98963053T patent/ES2202924T3/es not_active Expired - Lifetime
- 1998-12-11 US US09/210,556 patent/US6228859B1/en not_active Expired - Fee Related
- 1998-12-11 JP JP2000539025A patent/JP3504234B2/ja not_active Expired - Fee Related
- 1998-12-11 EP EP98963053A patent/EP1045849B1/en not_active Expired - Lifetime
- 1998-12-11 WO PCT/US1998/026444 patent/WO1999029694A1/en not_active Application Discontinuation
- 1998-12-11 PL PL98341108A patent/PL341108A1/xx unknown
- 1998-12-11 JP JP2000524287A patent/JP2001525412A/ja active Pending
- 1998-12-11 US US09/210,557 patent/US6211367B1/en not_active Expired - Lifetime
- 1998-12-11 TR TR2000/01706T patent/TR200001706T2/xx unknown
- 1998-12-11 BR BR9815171-1A patent/BR9815171A/pt not_active Application Discontinuation
- 1998-12-11 DK DK98963053T patent/DK1045849T3/da active
- 1998-12-11 AT AT98963053T patent/ATE244243T1/de not_active IP Right Cessation
- 1998-12-11 WO PCT/US1998/026293 patent/WO1999031102A1/en active IP Right Grant
- 1998-12-11 PT PT98963053T patent/PT1045849E/pt unknown
- 1998-12-11 CN CN98813362A patent/CN1284077A/zh active Pending
- 1998-12-11 EP EP98963114A patent/EP1045850A4/en not_active Withdrawn
-
2000
- 2000-06-09 NO NO20002998A patent/NO20002998L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9815171A (pt) | Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| TW200420542A (en) | A compound having TGF β inhibition activity and a medicinal composition containing the same | |
| BR0109851A (pt) | Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste | |
| MY148480A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| WO2003057698A3 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
| NZ334976A (en) | Benzonaphthyridine derivatives and their use for treating airway disorders and dermatoses | |
| MXPA04012965A (es) | Inhibidores virales. | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| YU29601A (sh) | Novi estri izvedeni iz supstituisanih fenil-cikloheksil jedinjenja | |
| BR0014060A (pt) | Derivado de quinolil propil piperidina, processo para preparação do mesmo, e, composição farmacêutica | |
| RS99203A (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| BR0111980A (pt) | Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda | |
| BR0211305A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto | |
| BR9806752A (pt) | Ftalazinonas. | |
| AP1541A (en) | New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors. | |
| IL127858A0 (en) | Muscarinic antagonists | |
| WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
| BR0011340A (pt) | Composto, processo para preparar o composto, composição, uso de um composto, e, método de tratar doenças alérgicas incluindo a asma brÈnquica, rinite, conjuntivite, dematose e urticária | |
| BRPI0411285A (pt) | composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios | |
| WO2002062777A3 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| WO2005046672A3 (fr) | Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose | |
| HK1033574A1 (en) | Anitumor agents | |
| AU1185801A (en) | Novel compounds | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |